2B70.F iShares NASDAQ US Biotechnology UCITS ETF
- Total assets
- 1.29B
- Expense ratio
- 0.36%
- Dividend yield
- 0.88%
- 1-year return
- +41.47%
- Holdings
- 10
- Since
- 2017
Fund data as reported by the issuer, updated Nov 11, 2026. Total assets are in the fund's base currency.
What does 2B70.F invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (93.4%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (97.4%)
- Top 3 holdings: 25.7% of the fund
Asset allocation
- US stocks 93.4%
- Non-US stocks 5.4%
- Cash 0.2%
Top holdings
- Gilead Sciences Inc 9.20%
- Amgen Inc 8.60%
- Vertex Pharmaceuticals Inc 7.85%
- Regeneron Pharmaceuticals Inc 6.25%
- Moderna Inc 5.77%
iShares NASDAQ US Biotechnology UCITS ETF performance
Sharpe ratio 0.92- This year
- +32.42%
- 1 year
- +41.47%
- 3 years
- +24.90%
- 5 years
- +9.43%
Volatility 18.4% over 1 year and 19.5% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
2B70.F price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About iShares NASDAQ US Biotechnology UCITS ETF
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Full fund profileiShares NASDAQ US Biotechnology UCITS ETF top holdings
48.8% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Gilead Sciences Inc GILD.US | Healthcare | United States | 9.20% |
| Amgen Inc AMGN.US | Healthcare | United States | 8.60% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 7.85% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 6.25% |
| Moderna Inc MRNA.US | Healthcare | United States | 5.77% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.65% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.43% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.36% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 2.00% |
| Roivant Sciences Ltd ROIV.US | Healthcare | United States | 1.69% |
2B70.F sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
2B70.F regional exposure
- North America97.4%
- Europe Developed2.7%
- United Kingdom2.3%
- Asia Developed0.1%
- Asia Emerging0.1%
- Australasia0.1%
- Africa/Middle East0.0%
Share of the stocks in the fund.
Company size
Average market cap 25.9B- Mega cap0.7%
- Big cap34.6%
- Medium cap32.7%
- Small cap23.3%
- Micro cap10.5%
iShares NASDAQ US Biotechnology UCITS ETF fund profile
- Fund name
- iShares NASDAQ US Biotechnology UCITS ETF
- Ticker
- 2B70.F
- Exchange
- Frankfurt Exchange
- Issuer
- BlackRock Asset Management Ireland - ETF
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Inception date
- Oct 19, 2017
- Trading currency
- EUR
- Expense ratio
- 0.36%
About iShares NASDAQ US Biotechnology UCITS ETF
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.